AstraZeneca (AZN) and Daiichi Sankyo said Monday its jointly developed and commercialized antibody drug conjugate, Enhertu, has been granted breakthrough therapy designation by the US Food and Drug Administration for adults with a certain type of breast cancer.
The designation was granted based on results from a phase 3 trial, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments